ストックスクリーナーアプリを入手
2.19
7.59%
-0.18
前日終値:
$2.37
開ける：
$2.4
24時間の取引高:
228.88K
Relative Volume:
0.85
時価総額：
$222.88M
収益：
$4.60M
当期純損益:
$-82.31M
株価収益率:
-2.6701
EPS:
-0.8202
ネットキャッシュフロー:
$-87.79M
1週間 パフォーマンス:
-1.79%
1か月 パフォーマンス:
-7.98%
6か月 パフォーマンス:
-31.35%
1年 パフォーマンス:
+1.39%
1日の値動き範囲:
$2.18
$2.40
1週間の範囲:
$2.18
$2.405
52週間の値動き範囲:
$2.03
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.19 | 234.08M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | BTIG Research | Buy |
| 2019-02-01 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-04 | 開始されました | UBS | Buy |
| 2018-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 開始されました | Credit Suisse | Outperform |
| 2016-10-18 | 開始されました | Jefferies | Buy |
| 2016-10-18 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Ac Immune Sa (ACIU) 最新ニュース
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
AC Immune SA (ACIU) Cash Flow - TradingKey
TradingKey - TradingKey
AC Immune SA (ACIU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACIU|AC Immune SA|Price:2.230|Chg%:-0.010 - TradingKey
AC Immune SA Revenue Breakdown – TRADEGATE:IMR - TradingView
AC Immune SA (ACIU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AC Immune Q1 2026 Earnings: Narrower Loss and Positive Surprise Highlight ProgressProduct Revenue Analysis - dars.gov.et
AC Immune (ACIU) Posts Modest Gain, Holds Above Key SupportDay Trade Opportunities - dars.gov.et
AC Immune Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock RisesAnalyst Coverage Count - dars.gov.et
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026 - The Manila Times
AC Immune brings three neurodegeneration studies to AAIC 2026 - Stock Titan
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEarnings Deceleration Risk - dars.gov.et
AC Immune: Holding Into A Make-Or-Break H2 2026 Readout (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune (ACIU) Slides 6.93% as Biotech Pressure Mounts – Key Support in FocusCollar Trade - dars.gov.et
Price to earnings forward of AC Immune SA – DUS:IMR - TradingView
Price to sales forward of AC Immune SA – NASDAQ:ACIU - TradingView
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program - TipRanks
Takeda-backed AC Immune (NASDAQ: ACIU) reports ACI-24 Alzheimer’s trial update - Stock Titan
ACIU: Promising Interim Results from AC Immune's Alzheimer's Stu - GuruFocus
AC Immune reports interim trial data for Alzheimer’s drug ACI-24 - Investing.com Australia
AC Immune Reports Interim 12-Month ABATE Data for ACI-24 in Prodromal Alzheimer’s Disease - Quiver Quantitative
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease - GlobeNewswire
AC Immune Q1 2026 Earnings: Narrowing Losses and Positive Pipeline MomentumProfit Cycle Analysis - dars.gov.et
Enterprise value to EBITDA forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to EBIT forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to book forward of AC Immune SA – NASDAQ:ACIU - TradingView
Enterprise value to revenue forward of AC Immune SA – NASDAQ:ACIU - TradingView
Price to earnings forward of AC Immune SA – NASDAQ:ACIU - TradingView
ACIU Forecast — Price Target — Prediction for 2027 - TradingView
AC Immune Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesTax Rate Impact - dars.gov.et
AC Immune SA (ACIU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Sparks Modest Stock GainGuidance Downgrade Alert - dars.gov.et
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACIU Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Alzheimer’s PipelineFree Cash Flow Trends - DonanımHaber
AC Immune SA (ACIU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AC Immune SA (ACIU) Valuation: PE, PB & Fair Value Analysis - TradingKey
AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACIU Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
June 2026 Penny Stocks To Watch For Potential Growth - simplywall.st
AC Immune (ACIU) director receives restricted share units and options grant - Stock Titan
AC Immune (ACIU) director receives new RSU and stock option grants - Stock Titan
AC Immune (ACIU) interim CEO Martin Zuegel granted RSUs and stock options - Stock Titan
AC Immune (ACIU) grants RSUs and stock options to director Buetler - Stock Titan
[Form 4] AC Immune SA Insider Trading Activity - Stock Titan
AC Immune Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Investor ResponseDividend Increase Stocks - newsline.com
INDV Stock: What Sublocade Growth Signals for 2026 - TradingView
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
Ac Immune Sa (ACIU) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):